As for AKT’s impact on lipogenesis, mTORC2, an activator of AKT, enhances de novo fatty acid synthesis in liver, leading to tumor malignancy.7 However, how mTORC2 regulates FA synthesis is not clearly understood.7 Our studies suggest that mTORC2 may activate AKT to cause FASN stabilization, thereby promoting de novo fatty acid synthesis. The gene discussed is FASN; the disease is neoplasm.